Companie

Natco Pharma Q1 net profit declines 39 per cent to ₹75 cr

PTI New Delhi | Updated on August 12, 2021

The board of directors has recommended an interim dividend of ₹2 per equity share

Drug firm Natco Pharma on Thursday reported a 38.57 per cent decline in its consolidated net profit at ₹75 crore for the quarter ended June 2021.

The company had posted a net profit of ₹122.1 crore for the corresponding period of the previous fiscal.

Consolidated total income of the company stood at ₹427.3 crore for the quarter under consideration. It was ₹582.1 crore for the same period a year ago, it added.

"The degrowth in sales can be partially attributed to the higher proportion of initial phase of pandemic exports to the US in Chloroquine Phosphate tablets and Oseltamivir Phosphate capsules in the revenues for the quarter ended June 30, 2020," Natco Pharma said.

The company has strong product launches both in export markets and domestic India business during the current financial year and expects to have good growth, it added.

The board of directors has recommended an interim dividend of ₹2 per equity share of ₹2 each, during the first quarter of FY 2021-22.

Shares of Natco Pharma ended at ₹ 1,041.45. up ₹30.90 or 3.06 per cent over its previous close on BSE on Thursday.

Published on August 12, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Quarterly Results
Natco Pharma Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.